AstraZeneca rare disease antibody shy of main goal in trial
(Alliance News) - AstraZeneca PLC on Wednesday announced that its antibody anselamimab did not achieve statistical significance in the overall patient population, thought it noted a "meaningful improvement" in all-cause mortality in a subgroup of patients. Read More